WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 18, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles , MD, has been appointed Executive Vice President, Research, Development, and
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 31, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga , MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs.
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr.
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 20, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , PhD has been appointed Senior Vice President and Chief Financial Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 17, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain , Esq. to its Board of Directors.
Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 11, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of
Two Data Sets to be Presented at 2022 Annual Meeting Poster Highlighting Updated Data from SORAYA Characterizing Anti-Tumor Activity Selected for Best of ASCO ® Program: Tumor Reduction in 71.4% of Patients and Preliminary Median Overall Survival of 13.8 Months in High Folate Receptor Alpha
Mirvetuximab Plus Bevacizumab Demonstrated Meaningful Efficacy in Recurrent FRα-Positive Ovarian Cancer Across a Broad Range of FRα Expression Regardless of Prior Treatment; Data to be Highlighted in Oral Presentation Additional Clinical Benefit Outcomes from Pivotal SORAYA Study Also Reported